cularized mass in the right temporal lobe with right-to-left shift of the vascular structures. Computerized tomography scanning was not available. Because of further neurological deterioration with symptoms consistent with intracranial hypertension (persisting vomiting, progressive somnolence, and bradycardia), the patient underwent intubation and was brought to the operating room.
First Operation. On exposure of the brain, the surgeon (M.G.Y.) observed edematous gyri with no signs of cortical pathological tissue or vascularization. Exploration with a needle revealed a cyst, localized in the medullary layer of the temporal lobe, which was punctured and drained. A total of 40 ml of xanthochromic fluid was drained, after which the temporal lobe collapsed. The tumor was reached via a 2-cm cortical incision in the middle temporal gyrus. Microsurgical exploration demonstrated a tumor localized in the lateral occipitotemporal gyrus, deeply subcortical and beneath the posterolateral wall of the inferior horn of the right lateral ventricle and extended to the trigone and posterior horn. Despite proximity, the tumor did not invade the hippocampus. The tumor was firm and fibrous, well circumscribed, and with little vascularization. Necrotic tissue with thrombosed veins was identified and easily resected using suction. Intraoperative inspection suggested macroscopic grosstotal tumor resection. The resection cavity measured 4 ϫ 5 ϫ 5 cm.
First Postoperative Course. The only persisting postoperative deficit was a homonymous left upper quadrantanopsia. The postoperative course was uneventful and the patient was discharged 7 days after surgery. He underwent postoperative fractionated whole-brain radiation therapy (telecobalt) of 5100 cGy with a local boost in the right temporoparietal region of 1440 cGy. Chemotherapy was not undertaken. Follow-up evaluations were conducted in a neurosurgical clinic on a yearly basis from 1975 to 1991. In the subsequent years, the patient sporadically visited his family physician. The first postoperative contrastenhanced CT scan, obtained in 1978, demonstrated the resection cavity but no residual or recurrent tumor. During the follow-up period between 1978 and 1990, the patient underwent a total of nine sessions in which CT scans were obtained (Fig. 1) . The first contrast-enhanced MR imaging study was performed in 1991, and thereafter the patient rejected further neuroimaging studies and was lost to neurosurgical follow up. During this time the patient's KPS score improved to 90. He resumed his job as a computer analyst and was active with hobbies including hiking and volleyball. During this period, he suffered from occasional episodes of headache, depression, and complex partial seizures with hallucinatory aura, which were treated intermittently with phenytoin.
Second Presentation and Examination. In October 2000, the 60-year-old patient presented with progressive dizziness, ataxia, and frontal headache. Neurological examination demonstrated decreased attention, lethargic speech, homonymous left upper quadrantanopsia (a known symptom), absence of left pupillary light reaction, papilledema, and ataxic gait. Functionally his KPS score deteriorated to 70. An emergency CT scan revealed a right cerebellar tumor that anteriorly displaced the fourth ventricle and caused right-to-left shift of the midline structures and dilation of the third and both lateral ventricles. No calcification was detected. The MR imaging findings confirmed those demonstrated on CT scanning. The tumor was isodense on T 1 -weighted and hyperintense in T 2 -weighted images, with moderate heterogeneity (Figs. 2  and 3 ). Cystic changes were present and the tumor margins were well defined. No recurrence of the right temporal GBM could be demonstrated. As shown in Fig. 3 , no evidence of cerebellar disease was visible retrospectively. Preoperative FDG-PET demonstrated high FDG uptake in the right cerebellum and very poor uptake in the right temporal region (Fig. 2) . Angiography revealed a hypervascularity in the inferior portion of the tumor. The posterior inferior cerebellar artery was displaced inferiorly. Preoperatively, the patient consented to undergo a right temporal biopsy procedure to obtain tissue from the prior GBM site.
Second Operation. A CT-guided stereotactic biopsy procedure of the GBM resection bed was performed targeting the posterior part of the temporal lobe. Three subcortical specimens could be obtained. The surgeon (J.F.) performed a right paramedian suboccipital craniotomy with the patient in the sitting position. An intraoperatively apparent gross-total tumor resection was achieved with the aid of intraoperative ultrasonography (Fig. 4A) . The tumor infiltrated almost the entire right cerebellar hemisphere. The patient could be extubated immediately after surgery, and his cerebellar symptoms and gait improved rapidly. After confirmation of the histological diagnosis, Second Postoperative Course. During the postoperative course the patient developed clinical signs of pulmonary embolism. A lung scintigraphy demonstrated bilateral multisegment and subsegmental pulmonary embolisms, and anticoagulation therapy was performed. The patient was transferred to a neurorehabilitation center; his a KPS score was 80. The patient refused postoperative radiotherapy and adjuvant chemotherapy. Six months after surgery, MR imaging and FDG-PET scanning demonstrated recurrence of the tumor adjacent to the cerebellopontine angle ( Fig. 4B and C) . At this point the patient's KPS score was 90. In the following months, the patient deteriorated and developed progressive gait disturbance, dysarthria, and later became somnolent and comatose. He died 9 months after the second surgery.
Pathological Examinations. The surgical specimen obtained 1975 was reexamined. On light microscopic examination, both frozen and paraffin-embedded sections showed a highly cellular tumor, nuclear pleomorphism, multinucleated giant cells, extensive vascular endothelial proliferation, and widespread areas of necrosis (Fig. 5) . There was high mitotic activity. Perivascular lymphocytic infiltrates were focally detectable. In addition to this predominating component with characteristic features of GBM, there was a minor component characterized by less cellularity and better differentiation. Molecular genetic analysis was performed retrospectively for this publication. Mutational analysis of exons 5 to 8 of the TP53 tumor suppressor showed no alteration. No EGFR gene amplification was found.
The second sampling included two stereotactic biopsy cores obtained in the right temporal region and three fractions of the actual tumor located in the right cerebellar hemisphere. On light microscopic examination of the site of the former GBM (right temporal region), there was insignificant gliosis, but neither GBM nor other glial or nonglial neoplasm was observed (Fig. 6 upper) . In contrast, all three biopsy fractions collected from the right cerebellar hemisphere displayed a highly cellular invasive tumor: densely packed small round cells with little cytoplasm and hyperchromatic nuclei (Fig. 6 lower) . Apoptotic and mitotic fractions were both high. Rosettes, either of Homer-Wright or Flexner-Wintersteiner type, were inconspicuous, whereas pseudorosettes were prominent. Remnants of the organotypic cerebellar foliage were seen in places, whereas overrun Purkinje cell layers were the only remainder in most parts. Ganglionic differentiation was not a prominent feature; thus, immunoreactivities for chromogranin A, synaptophysin, and neurofilament protein were either absent or very weak for the majority of neoplastic cells, but they were strongly reactive for CD56 and PGP 9.5. At the ultrastructural level, structures resembling synapses were present, whereas dense core granules were a rare finding consistent with negative immunoreactivity for chromogranin A. Hints of glial differentiation were missing. Therefore, a cerebellar recurrence of the former GBM was excluded, and, in the absence of significant reticulin fibers and large cells, the tumor qualified for the classic medulloblastoma Grade IV. Finally, the cytological examination of the cerebrospinal fluid was negative for tumor cells.
DISCUSSION
We report on a patient who had presented with a right temporal GBM at the age of 35 and underwent resection and fractionated whole-brain radiotherapy. The patient was admitted 26 years later with a medulloblastoma in the right cerebellum (within the radiotherapy field) but no signs of recurrence of the right temporal GBM. Neurodiagnostic studies such as MR imaging, PET scanning, and histopathological examination confirmed the absence of tumor recurrence.
Glioblastoma multiforme is the most malignant astrocytic tumor, composed of poorly differentiated neoplas-
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Long-term survival in a patient with GBM tic astrocytes. Histopathological features include cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. 3, 25 Glioblastoma multiforme may develop from WHO Grade II diffuse astrocytomas or anaplastic astrocytomas (secondary glioblastoma), but more frequently they manifest after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Glioblastoma multiforme was first described in 1863 by Virchow as a tumor of glial origin, 50 but the first comprehensive description was provided by Globus and Strauss. 17 Bailey and Cushing 2 changed the name from spongioblastoma multiforme to GBM, a term first used by Mallory in 1914. 31 Survival time in patients with gliomas depends mainly on the phenomenon of malignant progression, which was initially described by Tooth 49 in 1912. The prognosis has been a matter of controversy over the past century. In 1926 Bailey and Cushing 2 wrote: "The impression prevails in both laboratory and clinic that microscopic examination of a specimen removed at operation will not serve to predict, with a degree of certainty, the future course of development of a true tumor of the brain substance." In contrast, in patients in whom a primary GBM was diagnosed and resected, there is less controversy regarding the survival time. The median duration of survival is approxi- mately 50 months, 23, 35 and few patients live more than 5 years. 10 Long-term survivors of GBM have been anecdotally reported throughout the last 50 years. 11, 19 Recently, a summary of 30 patients who survived 10 years or longer after diagnosis was published (based on cases reported in the literature from 1990-2001). 38 Despite clinical and genetic studies, factors predictive of clinical outcome in GBM remained an elusive goal. The following six predictive factors have to be considered in long-term survival of GBM: age, KPS score, extent of resection, presence of necrosis, proliferation, and genetic alterations. 10, 25, 41, 42 In a review of 1003 glioblastoma biopsy specimens studied at the University Hospital Zurich, two thirds (70%) of the cases involved patients between 45 and 70 years of age (mean age at biopsy procedure 53 years). 25 More recently, the senior author (M.G.Y.) reported the outcome in a consecutive series of patients with GBM treated at the University Hospital Zurich (1967-1992). 52 Of 345 patients (male/female ratio 1.6:1) who underwent resection and postoperative radiotherapy, 71 patients (20.6%) were younger than 40 years of age. Twenty-two patients (6.3%) survived more than 3 years, seven (2%) patients survived 5 years, and only two patients (0.6%) were alive 10 years after treatment. Interestingly, these two patients were age 31 and 35 years, respectively, at the time of diagnosis. The former case (the only case in which survival was more that 25 years) is presented in this publication. In fact, this finding correlates with previous reports indicating that age is a strong prognostic factor. In patients younger than 45 years of age prognosis is better than in the elderly. 7, 39, 46 The reason for this might be an intrinsically more rapid malignant progression in elderly patients 43 and/or a higher frequency of secondary glioblastomas in younger patients. 7, 51 There is an inverse correlation between KPS score at the time of diagnosis and death rate (number of deaths divided by the total number of patient months of follow up). The ratio of death rate for highest and lowest scores is roughly 3, which is comparable to the 3.5 ratio demonstrated between older-and younger-age patients. 9 The duration of preoperative symptoms is also associated with survival. 48 Chandler, et al., 10 reviewed data obtained in 449 patients with GBM and studied possible factors associated with long-term survival. Twenty-two patients (5%) survived more than 5 years. The authors concluded that long-term survival most likely occurs in those who are young, have high KPS scores, and experience a long disease-free interval after the initial diagnosis. In 20 of 22 patients the KPS score was 80 or greater. Our patient was initially treated at age 35 years but presented with a low KPS score prior to the surgery. Nevertheless, his KPS score improved to 90 postoperatively and remained unchanged during the next 25 years.
The extent of resection as a predictive factor in the prognosis of patients with GBM remains controversial. Despite the fact that a significant survival difference has not been reported in all studies of cases in which the extent of resection has been great, 29 there is some evidence that complete resection favors longer survival. 1, 2, [4] [5] [6] [7] The authors of one study demonstrated that in cases in which postoperative MR imaging demonstrated residual tumor, there was a significantly higher (6.6-fold) risk of death (shorter survival time) than in those in which the entire contrast-enhancing tumor was shown to been removed. 1 Although the first CT study in our case could be performed almost 3 years after surgery in 1978, an enhancing lesion was not visualized in the right temporal region at that time nor on the subsequent CT and MR imaging studies performed until 2000 (Figs. 1-3) . Clearly in our case, surgical cytoreduction followed by radiotherapy led to a complete imaging-documented response, as evidenced by subsequent CT and MR imaging findings. Even if longterm survival after GBM resection is possible, the potential benefits of maximal resection must be balanced against the potential function-related effects on postoperative quality of life. New technological advances such as fluorescence-guided resection and intraoperative real-time MR imaging are promising advances to assist in safely achieving maximal tumor resection. 14, 47 The correct histopathological recognition of GBM has prognostic and therapeutic implications, because oligodendroglial tumors are more likely to respond favorably to chemotherapy. Histopathological reevaluation of patients harboring GBM in whom survival is long term should be considered mandatory. Kraus, et al., 28 reviewed a total of 52 cases of GBM in which survival was 12 months or greater and reported that 13 tumors (25%) were reclassified as anaplastic oligodendroglioma (WHO Grade III; seven cases) or anaplastic oligoastrocytoma (WHO Grade III; two cases). In addition, three were reclassified as anaplastic astrocytoma, and one was identified as anaplastic pilocytic astrocytoma. 28 The histopathological reevaluation of the tumor in our case confirmed the diagnosis of GBM.
The presence and extent of necrosis in GBM is associated with poor clinical outcome. 3, 7, 34 In our patient's tumor the area of necrosis was smaller than that usually found in elderly patients, reflecting a possible factor influencing the long-term survival in this case. With respect to proliferation, the tumor originally obtained in 1975 showed marked cellular and nuclear pleomorphism, multinucleated giant cells, high mitotic activity, and extensive vascular endothelial proliferation. Although these findings might correlate retrospectively with the clinical grade, they do not correlate with the outcome in our case. 8, 24, 33, 36 The presence of multinucleated giant cells may have contributed to a better outcome compared with that in other GBM cases. 7, 38 In our case molecular genetic analysis revealed no altered expression of TP53 and EGRF. Although some investigators have reported favorable prognosis in GBM if molecular alterations such as an increased frequency of TP53 mutations and deletions of chromosomal arm 17p are present, 32, 41, 51 and poorer prognosis if amplification with overexpression of EGFR is present, 12, 21 others have not confirmed these findings. 5, 26, 27, 40 Recently, Simmons, et al., 44 analyzed tumor tissue obtained in 110 cases of newly diagnosed GBM from two clinical protocols. Similar to results in other studies, the authors found no association of EGFR overexpression (as assessed by immunohistochemistry), p53 immunopositivity, or p53 mutation with survival in the entire sample. Epidermal growth factor receptor overexpression, however, showed trends toward a worse prognosis in patients younger than the median age but a better prognosis in those older than
Long-term survival in a patient with GBM the median age. In younger patients, they identified a statistically significant association of EGFR overexpression with worse survival in the p53-negative but not p53-positive tumors. In addition, the authors found that EGFR overexpression was negatively associated with survival only in the p53 wild-type cases. This complex relationship between EGFR and p53 in younger patients was also present in a multivariate analysis that incorporated additional prognostic variables. These results suggest that analysis of prognostic markers in GBM is complex, and maximal information may require analysis of subgroups based on age and the status of specific markers such as p53.
The patient described in this report presented at the age of 60 years with a cerebellar tumor 26 years after resection of a right temporal GBM. The MR image 9 years prior to this diagnosis indicated no lesion in the cerebellum (Fig.  3) . Based on MR imaging, FDG-PET scanning, and histopathological findings, the tumor was interpreted as a de novo medulloblastoma. Medulloblastomas are malignant, invasive embryonal tumors of the cerebellum with preferential manifestation in children, predominant neuronal differentiation, and an inherent tendency to metastasize via CSF pathways. 15 Seventy percent of medulloblastomas occur in individuals younger than 16 years of age. 4, 15 In adulthood, 80% of medulloblastomas arise in the 21 to 40-year-old age group. 16, 22 The estimated annual incidence of medulloblastoma in adults is 0.05 per 100. 4 Because this tumor rarely occurs beyond the fifth decade, our case is relevant for the neurosurgery literature. Of 89 consecutive cases with medulloblastoma treated at the University Hospital Zurich, only two patients (2.3%) were 60 years of age or older. 15 Cerebellar medulloblastoma diagnosed in our 60-year-old patient is undoubtedly a very uncommon finding in neurosurgical practice. It is difficult to address the role of radiotherapy in the pathogenesis of the medulloblastoma after such a long-term followup period in this case. 6 Because postradiation vascular changes in the white matter were not observed in the specimen, it can be assumed that the medulloblastoma was a de novo tumor.
Few data are available regarding treatment of adult medulloblastoma because its incidence is low, and most published series have concerned small samples and/or have been collected over a long period of time. 4 It is widely debated whether medulloblastoma in adults has a different prognosis from that in children. In some series the prognosis in adults was reported as the same as that in children, 2, 4 whereas others have reported better survival in adults because recurrences appear earlier in children. 4, 20, 37 Long-term survival is possible in adults with medulloblastoma; the reported rates range from 50 to 84% at 5 years and 40 to 50% at 10 years. 2, 3, 6, 8 Because the data in the literature are based on retrospective studies, treatments are neither randomized nor uniform; however, some treatment cornerstones have been identified. The first step is surgery, in which the resection should be as radical as possible; adjuvant 55-Gy radiotherapy must be targeted at the posterior fossa, with 36 Gy to the remaining cranial-spinal axis; adjuvant chemotherapy may be useful in patients at high risk of recurrence provided that it is administered before radiotherapy in moderate-high dosages and includes cisplatin, etoposide, and cyclophosphamide. 6 Although radiotherapy targeting the posterior fossa is standard, craniospinal radiotherapy is now controversial and many therapists restrict its use to high-risk patients. Chemotherapy is standard and can be administered before or after radiotherapy. 6 Recently, 57 adult patients with medulloblastoma were evaluated at the University of Texas M.D. Anderson Cancer Center over a 20-year period . 30 Statistical analysis of prognostic factors and overall survival was performed for a subgroup of 28 patients who were followed exclusively at their institution, between the time of diagnosis and death or last follow-up visit. Overall survival in these 28 patients was 91% at 3 years and 84% at 5 years, whereas median survival was not reached after a median follow-up period of 168 weeks (range 9-602 weeks). The authors reported a progression-free survival for all patients of 68% at 3 years and 62% at 5 years. Univariate analysis of clinical features, such as age, sex, extent of local disease, extent of resection, and use of adjuvant chemotherapy, did not identify any prognostic variables for survival among the 28 patients. In this retrospective study, adult medulloblastoma appeared to be associated with a favorable prognosis after treatment with maximally feasible resection followed by craniospinal irradiation. Considering the marked difference between survival and progression-free survival, the authors concluded that salvage therapy, usually involving combination chemotherapy, is of benefit. Nevertheless, results of adjuvant chemotherapy are inconclusive in most of the studies. 6 Greenberg, et al., 18 recently reviewed the cases of 17 adult patients with medulloblastoma who underwent surgery, craniospinal radiotherapy plus local boost, and one of two adjuvant chemotherapy regimens. Ten patients underwent treatment involving the "Packer protocol," which consisted of craniospinal radiotherapy plus weekly vincristine followed by eight cycles of cisplatin, lomustine, and vincristine. In seven patients POG protocol was applied, consisting of alternating courses of cisplatin/etoposide and cyclophosphamide/vincristine, followed by craniospinal radiotherapy. Median relapse-free survival for patients on the Packer protocol was 26 months, whereas for those on the POG regimen it was 48 months. The authors reported that POG and Packer protocols did not have a statistically significant difference in relapse-free or overall survival because of the small sample size. Because our patient refused further postoperative treatment, the possible benefits of craniospinal radiotherapy and adjuvant chemotherapy could not be evaluated. The patient experienced a 24-week progression-free period and survived 37 weeks after removal of the tumor.
